BEONE
LIVE

Serial Number

98746778

Owner

BeiGene Switzerland GMBH

Attorney

Kristen Ruisi

First Use Date

Nov 14, 2025

Filing Date

Sep 12, 2024

Add to watchlist:

No watchlists yet
View on USPTO

BEONE Trademark

Serial Number: 98746778 • Registration: 8287144

BEONE is a trademark filed by BeiGene Switzerland GMBH on September 12, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

BeiGene Switzerland GMBH

Aeschengraben 27
Basel 4051 , CH

Entity Type: 16

BEONE MEDICINES I GMBH (2 trademarks)

AESCHENGRABEN 27
BASEL 4051 , CH

Entity Type: 16

Trademark Details

Filing Date

September 12, 2024

Registration Date

June 2, 2026

First Use Anywhere

November 14, 2025

First Use in Commerce

November 14, 2025

Published for Opposition

April 15, 2025

Goods & Services

Research and development of new products for others; technological research in the field of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical research; scientific research in the nature of conducting clinical trials for others for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological research; quality control for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; electronic data storage; material testing

Pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; drugs in the nature of pharmaceutical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; medicines for human purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Injectable pharmaceuticals for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; crude drugs in the nature of pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Biochemical preparations for medical use for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases

Custom manufacturing services in the nature of chemical processing and production of medicines and pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases

Telemedicine services; health care; convalescent home services; physical therapy services; health counseling; pharmacy advice, namely, pharmaceutical advice

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 2, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 2, 2026 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 10, 2026 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 10, 2026 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Apr 28, 2026 SUPC
USE AMENDMENT FILED
Dec 4, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Dec 4, 2025 EISU
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jul 10, 2025 ASGN
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jul 9, 2025 ASCK
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 10, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 15, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 15, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 9, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 17, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 17, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 17, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 17, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 17, 2025 CNEA
ASSIGNED TO EXAMINER
Mar 12, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 24, 2025 NWOS
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Sep 16, 2024 TAEA
TEAS VOLUNTARY AMENDMENT RECEIVED
Sep 16, 2024 PARI
NEW APPLICATION ENTERED
Sep 12, 2024 NWAP